The FDA on February 13, 2024, approved ONIVYDE® (Irinotecan liposome) with Oxaliplatin, Fluorouracil, and Leucovorin, for the first-line treatment of metastatic pancreatic adenocarcinoma. ONIVYDE® is a product of Ipsen Biopharmaceuticals, Inc.
Bottom Ad
Advertisement
Subscribe
